Share
Seeger Weiss is proud to announce that Partner Parvin Aminolroaya has been appointed Co-Lead Counsel for Plaintiffs in the In Re: GLP-1 RAS Non-arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation and Counsel Max Kelly has been appointed to the Plaintiffs’ Executive Committee.
The litigation involves claims that GLP-1 receptor agonist drugs including Ozempic, Wegovy, Saxenda, and Trulicity caused patients to develop non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can result in sudden and permanent vision loss. Plaintiffs allege that the manufacturers failed to warn of this risk and are liable for failure to warn, design defect, and breach of warranties.
“We are honored by Judge Marston’s appointment and grateful for the trust placed in our team,” said Aminolroaya. “The vision loss our clients have suffered from GLP-1 medications is devastating and permanent. We are committed to working with our co-counsel to hold Novo Nordisk and Eli Lilly accountable for failing to warn patients of this serious risk.”
As a Partner at Seeger Weiss, Parvin has litigated some of the most significant pharmaceutical products liability cases in the country. Parvin currently serves as co-lead counsel in the related GLP-1 RAs Products Liability Litigation, where patients who took Ozempic, Wegovy, and similar drugs suffered serious gastrointestinal injuries, as well as co-lead counsel in the Elmiron Products Liability Litigation, a nationwide MDL alleging that the drug caused permanent vision injuries. She was previously part of the team appointed co-lead counsel in the landmark 3M Combat Arms Earplug Products Liability Litigation, the largest mass tort in American history.
Max Kelly is Counsel at Seeger Weiss, and focuses his practice on mass torts and class action lawsuits. Max played a significant role in the 3M Combat Arms Earplug Products Liability Litigation from its inception, working across all aspects of discovery and motion practice and serving on multiple trial teams that recovered seven-figure verdicts for injured servicemembers. He was centrally involved in the East Palestine Train Derailment Litigation against Norfolk Southern Railway, and has been centrally involved in the Allergan BIOCELL litigation, and in the original GLP-1 RAs Products Liability Litigation relating to gastrointestinal injuries.
Prior results do not guarantee or predict a similar outcome in any future manner.